Glynis Fisher

Glynis Fisher serves as a Contracting Officer responsible for managing the acquisition of biological products excluding diagnostic agents, ensuring compliance with federal procurement regulations and mission-critical supply chain requirements. In this role, she executes full lifecycle contract actions—from market research and solicitation development to award and closeout—supporting the agency’s objective to secure safe, effective, and timely access to essential biological therapeutics. Her acquisitions typically involve complex, high-stakes procurement actions requiring stringent regulatory alignment with FDA standards, cGMP compliance, and cold-chain logistics, reflecting her deep expertise in life sciences procurement. While specific contractor relationships are not publicly enumerated, Fisher engages with a broad spectrum of manufacturers and contract development and manufacturing organizations (CDMOs) capable of producing sterile, biologic, and advanced therapeutic products under stringent quality systems. Her procurement approach emphasizes vendor qualification through technical evaluations, past performance reviews, and supply chain resilience assessments, fostering long-term partnerships with firms demonstrating consistent regulatory compliance and production scalability. Fisher’s contracting portfolio reflects a 100% preference for non-set-aside awards, indicating a focus on full and open competition. This pattern suggests she prioritizes technical capability, production capacity, and regulatory readiness over socioeconomic set-asides, aligning with mission needs that demand specialized manufacturing expertise often found only among large-scale, established biopharmaceutical producers. Her primary NAICS specialization—325414, Biological Product (except Diagnostic) Manufacturing—underscores her deep technical domain expertise in procuring monoclonal antibodies, recombinant proteins, vaccines, and other advanced biologics. She routinely oversees contracts for GMP-compliant production, process validation, and batch release testing, requiring intimate knowledge of biologics development, sterility assurance, and federal biosecurity protocols. Fisher’s work is critical to sustaining national health security through reliable access to life-saving biological therapeutics.